What's in 3D Medicines (Sichuan) Co., Ltd.'s pipeline?

3D Medicines (Sichuan) Co., Ltd. has 6 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with 3D Medicines (Sichuan) Co., Ltd.'s portfolio?

Top competitors by shared drug class: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., AstraZeneca, GlaxoSmithKline, Jiangsu HengRui Medicine Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/3d-medicines-sichuan-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

3D Medicines (Sichuan) Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3D Medicines (Sichuan) Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
KN035 plus Gemcitabine & oxaliplatin	KN035 plus Gemcitabine & oxaliplatin	phase 3	PD-L1 inhibitor	PD-L1	Oncology
Gemcitabine & oxaliplatin	Gemcitabine & oxaliplatin	phase 3	Chemotherapy combination (nucleoside analog + platinum agent)	DNA (gemcitabine via ribonucleotide reductase inhibition and DNA incorporation; oxaliplatin via platinum-DNA adducts)	Oncology

Therapeutic area mix

Oncology · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 3 shared drug classes
Mabwell (Shanghai) Bioscience Co., Ltd. · 2 shared drug classes
AstraZeneca · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
Keymed Biosciences Co.Ltd · 2 shared drug classes
Celltrion · 2 shared drug classes
Innovent Biologics (Suzhou) Co. Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for 3D Medicines (Sichuan) Co., Ltd.:

Cite this brief

Drug Landscape (2026). 3D Medicines (Sichuan) Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/3d-medicines-sichuan-co-ltd. Accessed 2026-05-18.